Capstone Investment Advisors, LLC Nektar Therapeutics Transaction History

Capstone Investment Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $30,651 - $42,613	-1,818 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $549,961 - $1.06 Million	-38,007 Reduced 95.44%	1,818 $32,000
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $250,254 - $364,579	15,769 Added 65.55%	39,825 $860,000
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $192,604 - $413,115	11,390 Added 89.93%	24,056 $438,000
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $44,764 - $52,417	-1,444 Reduced 10.23%	12,666 $451,000

Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $260,313 - $382,063	8,243 Added 140.5%	14,110 $474,000
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $61,499 - $114,489	2,021 Added 52.55%	5,867 $193,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $178,685 - $263,412	3,846 New	3,846 $234,000
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $378,840 - $715,704	-6,600 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $151,932 - $399,300	6,600	6,600 $394,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capstone Investment Advisors, LLC with notifications on news.